相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
G. H. Lyman et al.
ANNALS OF ONCOLOGY (2013)
Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)
Arash Naeim et al.
BMC CANCER (2013)
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
Igor Bondarenko et al.
BMC CANCER (2013)
Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice
D. Almenar Cubells et al.
EUROPEAN JOURNAL OF CANCER CARE (2013)
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
Luigi Rossi et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2013)
Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer
P. Jenkins et al.
ANNALS OF ONCOLOGY (2012)
Prevention of Chemotherapy-Induced Neutropenia with Pegfilgrastim: Pharmacokinetics and Patient Outcomes
Bing-Bing Yang et al.
CHEMOTHERAPY (2012)
Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis
Nuttapong Ngamphaiboon et al.
MEDICAL ONCOLOGY (2012)
Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses
H. J. Henk et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin's Lymphoma Patients Receiving Pegfilgrastim
Jia Hui Ng et al.
ACTA HAEMATOLOGICA (2011)
Different Schedules of Granulocyte Growth Factor Support for Patients With Breast Cancer Receiving Adjuvant Dose-Dense Chemotherapy A Prospective Nonrandomized Study
Daniel Hendler et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients
Alexandre Chan et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2011)
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
Katy L. Cooper et al.
BMC CANCER (2011)
Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
John Pippen et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study
Hiangkiat Tan et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia
Emmanouil Saloustros et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
Sibylle Loibl et al.
SUPPORTIVE CARE IN CANCER (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
J. Crawford et al.
ANNALS OF ONCOLOGY (2010)
A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer
Denise A. Yardley et al.
CLINICAL BREAST CANCER (2010)
A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
J. Randolph Hecht et al.
CLINICAL COLORECTAL CANCER (2010)
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
Jan Braess et al.
BLOOD (2009)
Comparison of Hospitalization Risk and Associated Costs Among Patients Receiving Sargramostim, Filgrastim, and Pegfilgrastim for Chemotherapy-Induced Neutropenia
Mark L. Heaney et al.
CANCER (2009)
Risk of Hospitalization for Neutropenic Complications of Chemotherapy in Patients With Primary Solid Tumors Receiving Pegfilgrastim or Filgrastim Prophylaxis: A Retrospective Cohort Study
Derek Weycker et al.
CLINICAL THERAPEUTICS (2009)
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
D. Almenar et al.
EUROPEAN JOURNAL OF CANCER CARE (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Advances in the treatment of neutropenia
David C Dale
Current Opinion in Supportive and Palliative Care (2009)
Impact of primary prophylaxis on febrile neutropenia within community practices in the US
Dawn Hershman et al.
JOURNAL OF MEDICAL ECONOMICS (2009)
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer.: Results from the GEPARTRIO study
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2008)
Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)
Antonius A. Miller et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
Lionel Pinto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemodierapy: Results from a prospective community-based study
Stephen J. Noga et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim
Lodovico Balducci et al.
ONCOLOGIST (2007)
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use
Howard Ozer et al.
ONCOLOGIST (2007)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
MD Green et al.
ANNALS OF ONCOLOGY (2003)
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
FA Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients
P Viens et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
